S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

FDA Approves Sanofi Drug for Neurological Symptoms of Gaucher Disease

Sanofi has won U.S. approval for Infilbray, the first treatment for neurological symptoms caused by type 3 Gaucher disease, a rare inherited disorder that can affect coordination, speech and thinking. The once-daily oral medicine is approved for adults and children weighing at least 15 kilograms, or 33 pounds.

FDA Approves Sanofi Drug for Neurological Symptoms of Gaucher Disease

The drug, also known as venglustat, targets the buildup of fatty substances called glycosphingolipids. Sanofi said it is designed to act across the blood-brain barrier. Type 3 is one of the three major forms of Gaucher disease; according to the FDA, harmful substances build up in the brain and nervous system, and symptoms can worsen over time.

Sanofi said a late-stage clinical trial found significant improvements in certain neurological manifestations, including cognitive deficits and difficulty with coordination and balance. The company did not provide further trial details in its announcement.

Infilbray carries warnings and precautions for suicidal ideation and behavior, clouding of vision in younger patients, and adverse effects on fetal development during pregnancy, Sanofi said.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!